Potential target for breast cancer therapy

Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients. However, not all patients' tumors respond, with some becoming resistant over time. Researchers found a protein called P-Rex1 is crucial for signal transmission from ErbB receptors and is overexpressed in nearly 60 percent of breast cancer samples tested.

Read the whole article on Science Daily

More from Science Daily